**DIA Bayesian Scientific Working Group (BSWG)**

**F2F Meeting Agenda 2019**

*The DIA Bayesian Scientific Working Group (BSWG) was formed in 2011 with the vision to ensure that Bayesian methods are well-understood and broadly utilized for design and analysis throughout the medical product development process and to improve industrial, regulatory and economic decision making. The group is comprised of individuals from academia, industry and regulatory authorities.*

[*bayesianscientific.org/*](http://www.bayesianscientific.org/)

*Current Officers:*

*Chair - Fanni Natanegara*

*Vice-Chair/Chair-Elect - Amy Xia*

*Past Chair - Karen Price*

*Secretary - Pritibha Singh*

*Publication Chairs - Freda Cooner and Samiran Ghosh*

*Webmaster - Frank Liu*

*Free membership*

**Time:** Tuesday, July 30th , 4-6pm MST

**Location:** Hyatt Regency Denver Hotel (650 15th Street) – Centennial Ballroom

**4:00 pm - 4:30 pm** Welcome, BSWG Overview and Activities

**Presenter/Moderator:** Dr. Fanni Natanegara (Eli Lilly)

**4:30 pm - 5:30 pm** FDA Update on Complex Innovative Design (CID) with Panel Discussion (Q&A)

**Presenters:**

Dr. Dionne Price (FDA/CDER)

Dr. John Scott (FDA/CBER)

**Additional Panelists:**

Dr. Scott Berry (Berry Consultants)

Dr. Frank Harrell (Vanderbilt University)

**Moderator:** Dr. Freda Cooner (Amgen)

*Abstract: As part of the PDUFA VI agreement, FDA is conducting a Complex Innovative Trial Design (CID) Pilot Meeting Program to support the goal of facilitating and advancing the use of complex adaptive, Bayesian, and other novel clinical trial design. This session will discuss the program update since the Federal Register notice on August 29, 2018.*

**5:30 pm - 5:50 pm** DIA Adaptive Design Scientific Working Group Update

**Presenter:** Dr. Sammi Tang (Servier Pharmaceuticals)

**5:50 pm - 6:00 pm** Wrap-up

*Planning Committee:*

Freda Cooner (Amgen)

Amy LaLonde (Eli Lilly)

Melvin Munsaka (Abbvie) *Sponsors:*

Fanni Natanegara (Eli Lilly)

Karen Price (Eli Lilly)

Amy Xia (Amgen)